<DOC>
	<DOCNO>NCT02183168</DOCNO>
	<brief_summary>Study assess efficacy safety meloxicam suppository 15 mg daily , meloxicam tablet 15 mg daily compare Indomethacin suppository ( 50 mg daily ) patient ankylose spondylitis</brief_summary>
	<brief_title>Evaluation Efficacy Safety Meloxicam Suppository ( 15mg Daily ) Tablet ( 15 mg Daily ) Compared Indomethacin Suppository ( 50 mg Daily ) Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>Active ankylose spondylitis ( pain rat &gt; = 40 mm VAS increase least 30 % nonsteroidal antiinflammatory drug ( NSAIDs ) washout ) ) , without peripheral arthritis inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>